Real-world Data (RWD) Market to reach $4.07 billion by 2030: Coherent Market Insights

Advertisement

Real-world data (RWD) refers to information derived from sources outside the realm of conventional clinical trials, gaining growing significance in contemporary healthcare decision-making processes.

Burlingame, Oct. 06, 2023 (GLOBE NEWSWIRE) — According to Coherent Market Insights, global real-world data (RWD) market is estimated to be valued at US$ 1.59 billion in 2023 and is expected to exhibit a CAGR of 14.4% during the forecast period (2023-2030).

Real-world data (RWD) involves information collected from different sources and settings outside controlled clinical trials. It comprises data from insurance claims, electronic health records, wearable devices, patient registries, and more. RWD offers valuable insights into real-world patient experiences, disease patterns, and treatment outcomes, healthcare research support, development of evidence-based interventions, and decision-making.

Advertisement

Request a Sample Copy of the Research Report: https://www.coherentmarketinsights.com/insight/request-sample/6029

Market Drivers:

Increasing demand for evidence-based medicine to fuel market growth

There is a rise in emphasis on evidence-based medicine that relies on real-world evidence which comes from real-world data. Market players in healthcare industries, including regulators, healthcare providers, and payers are becoming more aware of the importance of using RWD for making informed decisions regarding comparative effectiveness, treatment effectiveness, cost-effectiveness, and safety. As a result, the demand for real world data solutions is increasing rapidly, which is further driving growth of the market.

Regulatory support and guidance to boost market pace

Regulatory agencies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) are making use of real-world evidence in regulatory decision making processes. These regulatory authorities have frameworks and guidelines for using RWE and RWD in regulatory submissions, post-market surveillance, and drug approvals. As a result, the demand for real-world data is rising, which in turn is expected to support growth of the market in the coming future.

Real-world Data (RWD) Market Report Coverage

Report Coverage Details
 Forecast Period  2023 to 2030
 Forecast Period 2023 to 2030 CAGR 14.4% 
 Market Size in 2023 $1.59 billion  
 2030 Value Projection $4.07 billion  
 Base Year 2022
 Historical Data for 2017 to 2021
 Segments covered  • By Source, By Application, By End User
 Growth Drivers   • Increasing Adoption of Electronic Health Records (EHRs)
• Growing Demand for Evidence-Based Medicine
• Regulatory Support and Guidance
• Advancements in Data Analytics and Technologies

Market Key Developments:

In 2022, IQIVA completed acquisition of Enlight Analytics, a leading provider of real-world data solutions for life sciences industry.

In 2021, PPD, Inc. which is now acquired by Thermo Fisher Scientific Inc. revealed that it has completed acquisition of Aetion, who provides RWD insights and analytics.

Buy Now & Get Exclusive Discount On This Report: https://www.coherentmarketinsights.com/insight/buy-now/6029

Market Opportunities:

Access to market and lucrative reimbursement policies are generating growth opportunities in the global real-world data (RWD) market. The use of real-world evidence derived from RWD demonstrates value and cost-effectiveness of medical devices and drugs for healthcare technology assessment agencies and payers. With this evidences, market access becomes easier and it also enables reimbursement negotiations. This further facilities the inclusion of new therapies in the coverage of healthcare. This in turn creates major opportunities in the global market.

Key Trends and Analysis of the Global Real-world Data (RWD) Market:

Growing advancements in AI and Data Analytics is a major trend in the global real-world data (RWD) market. RWD solutions are rapidly advancing in Data analytics techniques and tools, which includes machine learning and artificial intelligence. Due to these technologies, high sophisticated analysis of complex and large datasets is now possible, along with correlations and trends, and uncovering patterns that could not be possible with conventional statistical approaches. This trend is anticipated to grow in the global market over the forecast future.

Market Restrain:

Regulatory compliance and data privacy to limit market growth

Using real-world data creates concerns around data protection and patient privacy. Due to regulatory requirements, such as HIPAA and GDPR, stringent regulations on collection, storing, and use of patient are imposed everywhere. Complying with these regulations further create more complexity and increases cost of RWD initiatives, which further requires strong data de-identification as well as security measures for protecting patient privacy. This factor further limits growth of the global real-world data (RWD) market.

Request Customization of this Report: https://www.coherentmarketinsights.com/insight/request-customization/6029

Key Market Takeaways:

Global real-world data (RWD) market is expected to exhibit a CAGR of 14.4% during the forecast period. The real-world data (RWD) market is growing rapidly in response to the growing adoption of electronic health records (EHRs) by healthcare providers, leading to accumulation of large amount of patient data.

On the basis of Source, Electronic Health Records (EHRs) Segment is expected to dominate the market during the forecast period and this is attributed to the higher adoption of EHRs for obtaining real-world data.

On the basis of Application, Drug development and approvals Segment is expected to dominate the market during the forecast period and this is attributed to the rise in number of clinical trials, especially in cardiovascular and oncology therapeutics.

On the basis End User, Pharmaceutical and medical device companies Segment is expected to dominate the market during the forecast period and this is attributed to the rising importance of real-world data in drug approvals, assessment of drug performance in real-world settings, and prevention of costly drug recalls.

On the basis of Geography, North America is expected to hold a dominant position over the forecast period, due to rise in prevalence of chronic diseases, stringent approval regulations for drugs, and availability of well-developed healthcare infrastructure in the region.

Key players operating in the global real-world data (RWD) market include SAS Institute Inc., IQVIA Holdings Inc., Palantir Technologies Inc., Optum, Inc. (a subsidiary of UnitedHealth Group), Evidera, Inc., Cerner Corporation, Syneos Health Inc., Flatiron Health, Inc. (a subsidiary of Roche), Tempus Labs Inc., and IBM Corporation.

Detailed Segmentation:

  • Global Real World Data Market, By Source:
    • Electronic health records (EHRs)
    • Claims data
    • Pharmacy data
    • Patient-reported outcomes (PROs)
    • Disease registries
    • Other sources
  • Global Real World Data Market, By Application:
    • Drug development and approvals
    • Market access and reimbursement/coverage decisions
    • Post-market surveillance
    • Clinical research
    • Other applications
  • Global Real World Data Market, By End User:
    • Pharmaceutical and medical device companies
    • Healthcare payers
    • Healthcare providers
    • Government agencies
    • Others
  • Global Real World Data Market, By Region:
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • Italy
      • U.K.
      • France
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • Australia
      • India
      • ASEAN
      • South Korea
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • Israel
      • South Africa
      • Rest of Middle East & Africa

Related Market Intelligence Reports:

Shigella Test Kit Market, By Product Type (Lateral flow assays, Enzyme-linked immunosorbent assay (ELISA), Polymerase chain reaction (PCR) assay, Others), By Technology (Conventional diagnostic tests, Nucleic acid-based tests, Others), By End Users (Hospitals, Diagnostic laboratories, Research institutes, Others), and By Geography, Market Size And Share Analysis – Growth Trends And Forecasts (2023 – 2030)

Biopharmaceutical CMO and CRO Market, By Source (Mammalian and Non-mammalian), By Service (Contract Manufacturing and Contract Research), and By Product (Biologics and Biosimilars), and By Geography, Market Size And Share Analysis – Growth Trends And Forecasts (2023 – 2030)

Digital Diabetes Management Market, By Type (Handheld Devices and Wearable Devices) and By Product (Continuous Blood Glucose Monitoring Systems, Smart Glucose Meter, Smart Insulin Pumps, Smart Insulin Pens and Apps), and By Geography, Market Size And Share Analysis – Growth Trends And Forecasts (2023 – 2030)

Browse through Coherent Market Insights Healthcare IT Research Reports.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Follow Us: LinkedInTwitter

CONTACT: Mr. Shah Senior Client Partner – Business Development Coherent Market Insights Phone: US: +1-206-701-6702 UK: +44-020-8133-4027 Japan: +81-050-5539-1737 India: +91-848-285-0837 Email: [email protected] Website: https://www.coherentmarketinsights.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.